MEPs Against Cancer Round Table 

Key Determinants of Inequalities in Cancer Survival across Europe:

The Latest Results of the Eurocare 5 Study

 (Coincides with publication of Lancet Oncology Article)


MAC Press Release


MAC Roundtable Conclusions





05 December 2013, 14.00 to 16.15, Room Asp5f385


This event was hosted by Alojz Peterle MEP who sent the following letter concerning the outcome of the MAC meeting to fellow members of the European Parliament:

"Dear Colleagues,

On 5 December 2013 the MEPs Against Cancer group held a roundtable on “Key determinants of Inequalities in cancer Survival across Europe” where the latest results from EUROCARE, the widest collaborative research project comparing cancer survival by country in Europe, were presented.

EUROCARE 5 results were presented, published also in the Lancet Oncology magazine, which shown that the number of adults surviving at least 5 years after the diagnosis has increased steadily over time in all regions of Europe from 1999 to 2007 and yet cancer survival still varies widely between European countries. Despite the promising increase of childhood cancer survival in Eastern Europe, the rate in this region is still  10% to 20% lower than in Western Europe. Please find the conclusions of the study in the attached document.

High representatives from DG SANCO, DG Research and the Joint Research Centre, EUROCARE leaders, cancer registry directors and researchers from Slovakia, Lithuania, Estonia, Croatia, Bulgaria, major EU cancer stakeholders, including ECCO, SIOP-E, ESSO, ECPC, ECL, EPHA, EONS, OECI, EPAAC, MPE, ENCR among others, and endorsed by ESO, ESTRO and ESMO sought to draw attention to the inequalities across the EU ahead of the European Elections and discuss solutions.

Given our views, we decided to support the following high priorities for the future decisions in cancer health policy:

  • International studies on population-based cancer survival are vital to disclose inequalities across European countries and are based exclusively on data from population cancer registries.
  • Public health research conducted on the basis of population-based disease registries shall not be impeded by the new proposal on the General Data Protection Regulation.
  • Ad hoc-studies to investigate the reasons of such inequalities (e.g. access to early diagnosis and optimal treatments, organization of health care delivery).
  • New studies to address emerging issues related to the management of elderly patients and of survivorship including quality of life.
  • Promotion of twinning programmes i.e. pairing medical institutions in high-income countries with those in low/middle-income countries to reduce the childhood cancer survival gap in Europe.
  • Follow evidence-based clinical guidelines covering the whole patient pathway to ensure good clinical cancer care: early detection diagnosis, treatment, monitoring and palliative care. Preventive strategies may also be a vital phase of cancer care.
  • Organizing cancer services to ensure that all patients receive high quality cancer care, strengthening the governance of cancer care, monitoring and benchmarking performance through better data.

Thank you for your attention and cooperation, I look forward to a fruitful collaboration on the items above.

Kind regards,"

Alojz Peterle MEP

President of the MEPs Against Cancer




The Latest Results of the Eurocare 5 Study
05 December 2013 (Register at 13.30) 14.00 to 16.15 Room Asp5f385
Hosted by Alojz Peterle MEP and
14.00 – 14.05
MEP Alojz Peterle
14.05 – 14.10
Importance of Cancer Registries in Europe
14.10 – 14.20
The rationale and scopes of EUROCARE 5
M. Sant, Head of Analytical Epidemiology and Health Impact, INT Milan
14.20 – 14.30
Adult survival
R. De Angelis, Head of Epidemiology Unit, ISS, Rome
14.30 – 14.40
Childhood Survival
G. Gatta, Head of Evaluative Epidemiology, INT Milan
14.40 – 15.40
Next steps
The voice of Key EU cancer stakeholders
F. Berrino, former Head of Preventive Medicine Dept, INT Milan, EUROCARE SC Chair
Alojz Peterle and Franco Berrino (moderators)
with Cancer Registry directors from Bulgaria, Croatia, the Baltic countries, Italy, Poland, Romania, Slovakia, Spain, UK&Ireland
and with
K. BERKOUK DG Research and Innovation
M. Bettio Joint Research Centre
15.40 – 15.55
MEP statements
Attending MEPs
15.55 – 16.05
16.05 – 16.15
16.15 – 17.00
Questions from the Media
Conclusions and Wrap Up
Networking Coffee
A. Peterle MEP
All are welcome
 The Association of European Cancer Leagues implements activities which receive financial support from the European Commission under an Operating Grant from the European Union's Health Programme (2014-2020). The views expressed on our website and reports do not necessarily reflect the official views of the EU institutions.
EU flag and co-funded by health programme LOGO  




The text of this webpage is available for modification and reuse under the terms of the Creative Commons Attribution-Sharealike 3.0 Unported License and the GNU Free Documentation License (unversioned, with no invariant sections, front-cover texts, or back-cover texts).


Go to top